Cargando…

CAR T-cell therapy for secondary CNS DLBCL

Management of secondary central nervous system (SCNS) involvement in relapsed or refractory aggressive B-cell lymphomas remains an area of unmet medical need. We report a single-center retrospective analysis of 7 adult patients with SCNS lymphoma (SCNSL) who underwent chimeric antigen receptor (CAR)...

Descripción completa

Detalles Bibliográficos
Autores principales: Ahmed, Gulrayz, Hamadani, Mehdi, Shah, Nirav N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8714710/
https://www.ncbi.nlm.nih.gov/pubmed/34551065
http://dx.doi.org/10.1182/bloodadvances.2021005292
_version_ 1784623958681714688
author Ahmed, Gulrayz
Hamadani, Mehdi
Shah, Nirav N.
author_facet Ahmed, Gulrayz
Hamadani, Mehdi
Shah, Nirav N.
author_sort Ahmed, Gulrayz
collection PubMed
description Management of secondary central nervous system (SCNS) involvement in relapsed or refractory aggressive B-cell lymphomas remains an area of unmet medical need. We report a single-center retrospective analysis of 7 adult patients with SCNS lymphoma (SCNSL) who underwent chimeric antigen receptor (CAR) T-cell therapy for their refractory disease, and we describe the safety of whole brain radiation therapy (WBRT) as a bridging therapy. Six patients (85.7%) achieved a complete response at day 28, and 1 patient had progressive disease. The median progression-free survival was 83 days (range, 28-219 days), and median overall survival was 129 days (range, 32-219 days). Three patients died as a result of disease progression. Of the 5 patients who received WBRT as bridging therapy, 3 had no immune effector cell–associated neurotoxicity syndrome (ICANS), but 2 patients had grade 1 or grade 3 ICANS. No grade 4 ICANS was reported in this subset of patients. We conclude that SCNSL should not preclude patients from receiving CAR T-cell therapy as a treatment option because of concerns regarding ICANS, and bridging with WBRT is not associated with increased ICANS.
format Online
Article
Text
id pubmed-8714710
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher American Society of Hematology
record_format MEDLINE/PubMed
spelling pubmed-87147102021-12-29 CAR T-cell therapy for secondary CNS DLBCL Ahmed, Gulrayz Hamadani, Mehdi Shah, Nirav N. Blood Adv Stimulus Report Management of secondary central nervous system (SCNS) involvement in relapsed or refractory aggressive B-cell lymphomas remains an area of unmet medical need. We report a single-center retrospective analysis of 7 adult patients with SCNS lymphoma (SCNSL) who underwent chimeric antigen receptor (CAR) T-cell therapy for their refractory disease, and we describe the safety of whole brain radiation therapy (WBRT) as a bridging therapy. Six patients (85.7%) achieved a complete response at day 28, and 1 patient had progressive disease. The median progression-free survival was 83 days (range, 28-219 days), and median overall survival was 129 days (range, 32-219 days). Three patients died as a result of disease progression. Of the 5 patients who received WBRT as bridging therapy, 3 had no immune effector cell–associated neurotoxicity syndrome (ICANS), but 2 patients had grade 1 or grade 3 ICANS. No grade 4 ICANS was reported in this subset of patients. We conclude that SCNSL should not preclude patients from receiving CAR T-cell therapy as a treatment option because of concerns regarding ICANS, and bridging with WBRT is not associated with increased ICANS. American Society of Hematology 2021-12-28 /pmc/articles/PMC8714710/ /pubmed/34551065 http://dx.doi.org/10.1182/bloodadvances.2021005292 Text en © 2021 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.
spellingShingle Stimulus Report
Ahmed, Gulrayz
Hamadani, Mehdi
Shah, Nirav N.
CAR T-cell therapy for secondary CNS DLBCL
title CAR T-cell therapy for secondary CNS DLBCL
title_full CAR T-cell therapy for secondary CNS DLBCL
title_fullStr CAR T-cell therapy for secondary CNS DLBCL
title_full_unstemmed CAR T-cell therapy for secondary CNS DLBCL
title_short CAR T-cell therapy for secondary CNS DLBCL
title_sort car t-cell therapy for secondary cns dlbcl
topic Stimulus Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8714710/
https://www.ncbi.nlm.nih.gov/pubmed/34551065
http://dx.doi.org/10.1182/bloodadvances.2021005292
work_keys_str_mv AT ahmedgulrayz cartcelltherapyforsecondarycnsdlbcl
AT hamadanimehdi cartcelltherapyforsecondarycnsdlbcl
AT shahniravn cartcelltherapyforsecondarycnsdlbcl